Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Review, H1 2015

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Review, H1 2015', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Wet (Neovascular / Exudative) Macular Degeneration Overview 9

Therapeutics Development 10

Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration-Overview 10

Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration-Comparative Analysis 11

Wet (Neovascular / Exudative) Macular Degeneration-Therapeutics under Development by Companies 12

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Wet (Neovascular / Exudative) Macular Degeneration-Products under Development by Companies 20

Wet (Neovascular / Exudative) Macular Degeneration-Companies Involved in Therapeutics Development 24

Alcon, Inc. 24

Allergan, Inc. 25

AlphaMab Co., Ltd 26

Amakem NV 27

Avalanche Biotechnologies, Inc. 28

Bayer AG 29

BIOCAD 30

Boehringer Ingelheim GmbH 31

Charlesson LLC. 32

Circadian Technologies Limited 33

Clearside BioMedical, Inc. 34

EyeCyte, Inc. 35

F. Hoffmann-La Roche Ltd. 36

Genzyme Corporation 37

GlaxoSmithKline plc 38

iCo Therapeutics Inc. 39

Icon Bioscience, Inc. 40

Iconic Therapeutics, Inc. 41

Intas Pharmaceuticals Ltd. 42

Kala Pharmaceuticals, Inc. 43

Lpath, Inc. 44

Mesoblast Limited 45

Neurotech Pharmaceuticals, Inc. 46

Novartis AG 47

Ohr Pharmaceutical Inc. 48

Ophthotech Corp. 49

Oxford BioMedica plc 50

PanOptica, Inc. 51

Pfenex Inc. 52

Pfizer Inc. 53

pSivida Corp. 54

Quark Pharmaceuticals, Inc. 55

Regeneron Pharmaceuticals, Inc. 56

ReGenX Biosciences, LLC 57

Resolvyx Pharmaceuticals, Inc 58

Santen Pharmaceutical Co., Ltd. 59

Sanwa Kagaku Kenkyusho Co., Ltd. 60

Tacere Therapeutics, Inc. 61

ThromboGenics NV 62

TRACON Pharmaceuticals, Inc. 63

TWi Pharmaceuticals, Inc. 64

DWet (Neovascular / Exudative) Macular Degeneration-Therapeutics Assessment 65

Assessment by Monotherapy Products 65

Assessment by Target 66

Assessment by Mechanism of Action 69

Assessment by Route of Administration 72

Assessment by Molecule Type 74

Drug Profiles 76

abicipar pegol-Drug Profile 76

AC-301-Drug Profile 78

aflibercept (recombinant)-Drug Profile 79

AGN-151200-Drug Profile 82

ALG-1001-Drug Profile 83

AMA-0428-Drug Profile 85

ARC-1905-Drug Profile 86

AVA-101-Drug Profile 87

AVA-201-Drug Profile 89

bertilimumab-Drug Profile 90

bevacizumab biosimilar-Drug Profile 92

BI-144807-Drug Profile 93

BI-30089-Drug Profile 94

C16Y Peptide-Drug Profile 95

CLT-005-Drug Profile 96

conbercept-Drug Profile 97

DE-120-Drug Profile 99

doxorubicin pegylated nanoparticle-Drug Profile 100

EC-200-Drug Profile 101

EC-400-Drug Profile 102

ENV-705-Drug Profile 104

fluocinolone acetonide-Drug Profile 105

GB-101-Drug Profile 107

Gene Therapy for Wet Age-Related Macular Degeneration-Drug Profile 108

GZ-402663-Drug Profile 109

hI-con1-Drug Profile 110

HMR-59-Drug Profile 111

LFG-316-Drug Profile 112

Lpathomab-Drug Profile 114

LT-1009-Drug Profile 115

MPC-MICRO-IO-Drug Profile 119

NM-9405-Drug Profile 120

NT-503-Drug Profile 121

NT-506-Drug Profile 122

ocriplasmin (recombinant)-Drug Profile 123

OPT-302-Drug Profile 126

PAN-90806-Drug Profile 127

pazopanib hydrochloride-Drug Profile 128

pegpleranib sodium-Drug Profile 133

PF-05206388-Drug Profile 135

PF-655-Drug Profile 136

ranibizumab biosimilar-Drug Profile 138

ranibizumab biosimilar-Drug Profile 139

ranibizumab biosimilar-Drug Profile 140

ranibizumab biosimilar-Drug Profile 141

REGN-21763-Drug Profile 142

regorafenib-Drug Profile 143

RetinoStat-Drug Profile 146

RG-7716-Drug Profile 147

RTH-258-Drug Profile 148

RX-20001-Drug Profile 150

SK-1011-Drug Profile 151

Small Molecule to Inhibit Receptor Tyrosine Kinase for Wet Age-Related Macular Degeneration-Drug Profile 152

Small Molecules for Age Related Macular Degeneration-Drug Profile 153

Small Molecules to Inhibit VEGF and PDGF for Wet AMD-Drug Profile 154

Small Molecules to Inhibit VEGF for Wet AMD-Drug Profile 156

squalamine lactate-Drug Profile 158

TRC-105-Drug Profile 161

triamcinolone acetonide-Drug Profile 163

TT-211-Drug Profile 164

TT-231-Drug Profile 165

X-82-Drug Profile 166

XV-615-Drug Profile 167

Wet (Neovascular / Exudative) Macular Degeneration-Recent Pipeline Updates 168

Wet (Neovascular / Exudative) Macular Degeneration-Dormant Projects 209

Wet (Neovascular / Exudative) Macular Degeneration-Discontinued Products 211

Wet (Neovascular / Exudative) Macular Degeneration-Product Development Milestones 212

Featured News & Press Releases 212

Appendix 221

Methodology 221

Coverage 221

Secondary Research 221

Primary Research 221

Expert Panel Validation 221

Contact Us 222

Disclaimer 222

List of Tables

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2015 14

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Development by Companies, H1 2015 (Contd..3) 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Alcon, Inc., H1 2015 28

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Allergan, Inc., H1 2015 29

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by AlphaMab Co., Ltd, H1 2015 30

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Amakem NV, H1 2015 31

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Avalanche Biotechnologies, Inc., H1 2015 32

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Bayer AG, H1 2015 33

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by BIOCAD, H1 2015 34

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Boehringer Ingelheim GmbH, H1 2015 35

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Charlesson LLC., H1 2015 36

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Circadian Technologies Limited, H1 2015 37

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Clearside BioMedical, Inc., H1 2015 38

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by EyeCyte, Inc., H1 2015 39

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 40

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Genzyme Corporation, H1 2015 41

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by GlaxoSmithKline plc, H1 2015 42

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by iCo Therapeutics Inc., H1 2015 43

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Icon Bioscience, Inc., H1 2015 44

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Iconic Therapeutics, Inc., H1 2015 45

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 46

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 47

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Lpath, Inc., H1 2015 48

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Mesoblast Limited, H1 2015 49

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 50

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Novartis AG, H1 2015 51

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Ohr Pharmaceutical Inc., H1 2015 52

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Ophthotech Corp., H1 2015 53

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Oxford BioMedica plc, H1 2015 54

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by PanOptica, Inc., H1 2015 55

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Pfenex Inc., H1 2015 56

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Pfizer Inc., H1 2015 57

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by pSivida Corp., H1 2015 58

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 59

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 60

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by ReGenX Biosciences, LLC, H1 2015 61

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 62

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 63

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015 64

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by Tacere Therapeutics, Inc., H1 2015 65

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by ThromboGenics NV, H1 2015 66

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 67

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline by TWi Pharmaceuticals, Inc., H1 2015 68

Assessment by Monotherapy Products, H1 2015 69

Number of Products by Stage and Target, H1 2015 71

Number of Products by Stage and Mechanism of Action, H1 2015 74

Number of Products by Stage and Route of Administration, H1 2015 77

Number of Products by Stage and Molecule Type, H1 2015 79

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics-Recent Pipeline Updates, H1 2015 172

Wet (Neovascular / Exudative) Macular Degeneration-Dormant Projects, H1 2015 213

Wet (Neovascular / Exudative) Macular Degeneration-Dormant Projects (Contd..1), H1 2015 214

Wet (Neovascular / Exudative) Macular Degeneration-Discontinued Products, H1 2015 215

List of Figures

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2015 14

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 69

Number of Products by Top 10 Targets, H1 2015 70

Number of Products by Stage and Top 10 Targets, H1 2015 70

Number of Products by Top 10 Mechanism of Actions, H1 2015 73

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 73

Number of Products by Top 10 Routes of Administration, H1 2015 76

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 77

Number of Products by Top 10 Molecule Types, H1 2015 78

Number of Products by Stage and Top 10 Molecule Types, H1 2015 78

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alcon, Inc.

Allergan, Inc.

AlphaMab Co., Ltd

Amakem NV

Avalanche Biotechnologies, Inc.

Bayer AG

BIOCAD

Boehringer Ingelheim GmbH

Charlesson LLC.

Circadian Technologies Limited

Clearside BioMedical, Inc.

EyeCyte, Inc.

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

GlaxoSmithKline plc

iCo Therapeutics Inc.

Icon Bioscience, Inc.

Iconic Therapeutics, Inc.

Intas Pharmaceuticals Ltd.

Kala Pharmaceuticals, Inc.

Lpath, Inc.

Mesoblast Limited

Neurotech Pharmaceuticals, Inc.

Novartis AG

Ohr Pharmaceutical Inc.

Ophthotech Corp.

Oxford BioMedica plc

PanOptica, Inc.

Pfenex Inc.

Pfizer Inc.

pSivida Corp.

Quark Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

ReGenX Biosciences, LLC

Resolvyx Pharmaceuticals, Inc

Santen Pharmaceutical Co., Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

Tacere Therapeutics, Inc.

ThromboGenics NV

TRACON Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc.

Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Products under Development, Key Players in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Wet (Neovascular / Exudative) Macular Degeneration Pipeline Overview, Wet (Neovascular / Exudative) Macular Degeneration Pipeline, Wet (Neovascular / Exudative) Macular Degeneration Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com